Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Madrigal Pharmaceuticals (MDGL) over the last 11 years, with Sep 2025 value amounting to $857,000.

  • Madrigal Pharmaceuticals' Capital Expenditures rose 10.01% to $857,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 14.81%. This contributed to the annual value of $1.5 million for FY2024, which is 1.15% down from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Capital Expenditures is $857,000, which was up 339.49% from $195,000 recorded in Q4 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' Capital Expenditures peaked at $1.0 million during Q4 2023, and registered a low of $2,000 during Q2 2021.
  • For the 3-year period, Madrigal Pharmaceuticals' Capital Expenditures averaged around $422,000, with its median value being $339,000 (2023).
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Capital Expenditures plummeted by 85.99% in 2021, and later soared by 5,050.00% in 2022.
  • Madrigal Pharmaceuticals' Capital Expenditures (Quarterly) stood at $113,000 in 2021, then tumbled by 74.34% to $29,000 in 2022, then spiked by 3,472.41% to $1.0 million in 2023, then crashed by 81.18% to $195,000 in 2024, then grew by 10.01% to $857,000 in 2025.
  • Its last three reported values are $857,000 in Q3 2025, $195,000 for Q4 2024, and $779,000 during Q3 2024.